rabbit polyclonal antibody against cd206  (Servicebio Inc)

Journal: Frontiers in Immunology

Article Title: The interplay of inflammation and placenta in maternal diabetes: insights into Hofbauer cell expression patterns

doi: 10.3389/fimmu.2024.1386528

Figure Lengend Snippet: Hofbauer cells in the placenta. The routine staining shows typical morphology and localization of HBCs. Their presence was confirmed using CD206. All microphotographs are magnified 200x, details are 400x. HBCs are marked by arrowheads.

Article Snippet: The following primary antibodies were used: rabbit polyclonal antibodies against CD206 (Abcam; ab64693) at a dilution of 1:1000, IL-10 (Abcam; ab34843) at a dilution of 1:400, IL-1β (Novus Biologicals, NBP1-19775) at a dilution of 1:100, CYP2C8 (ProteinTech, 16546-1-AP) at a dilution of 1: 50 and CYP2J2 (Abcam, ab151996) at 1:100 dilution and mouse monoclonal antibody against CD86 (Abcam; ab220188) at 1:50 dilution, CYP2C9 (Novus Biologicals, NBP2-01381) at 1:400 dilution and sEH (Santa Cruz, sc166916) at 1:200 dilution.

Techniques: Staining

Journal: Cells

Article Title: The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT

doi: 10.3390/cells10123393

Figure Lengend Snippet: GRP94 and CD206 are co-expressed in murine and some human TNBC tumors. ( A ). Representative immunostaining of GRP94 (red) and CD206 (green) in 4T1 tumor-bearing mice ( n = 8). ( B ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor infiltrated with CD206 + M2-like macrophages ( n = 3). ( C ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor non infiltrated with CD206 + M2-like macrophages ( n = 3).

Article Snippet: The tissues were then stained with a rabbit polyclonal antibody directed against CD206 (1/100; LS-B9805-200, Clinisciences, Nanterre, France), GRP94 antibody (1/100; LS B3418, Clinisciences, Nanterre, France), or against CD8 (1/200; NBP2-29475, Novusbio, Noyal Châtillon sur Seiche, France) overnight at 4 °C.

Techniques: Immunostaining

Journal: Cells

Article Title: The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT

doi: 10.3390/cells10123393

Figure Lengend Snippet: SPECT/CT imaging with 99m Tc-Tilmanocept can specifically detect CD206 + cells in vivo. ( A ) Representative SPECT/CT images of 4T1 tumor-bearing mice at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20× excess of cold Tilmanocept (4T1 blocking, n = 6). Results are presented as the median with the interquartile range. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups (* p = 0.0293). ( B ) The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice at 24 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20x excess of cold Tilmanocept (4T1 blocking, n = 6) measured by gamma counting (*** p = 0.0007).

Article Snippet: The tissues were then stained with a rabbit polyclonal antibody directed against CD206 (1/100; LS-B9805-200, Clinisciences, Nanterre, France), GRP94 antibody (1/100; LS B3418, Clinisciences, Nanterre, France), or against CD8 (1/200; NBP2-29475, Novusbio, Noyal Châtillon sur Seiche, France) overnight at 4 °C.

Techniques: Single Photon Emission Computed Tomography, Imaging, In Vivo, Injection, Blocking Assay

Journal: Cells

Article Title: The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT

doi: 10.3390/cells10123393

Figure Lengend Snippet: GRP94 inhibition by PU-WS13 induces a decrease in 99m Tc-Tilmanocept tumor uptake in vivo. ( A ). Representative SPECT/CT images of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept. Tumors are highlighted with circles. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups. Results are presented as the median with the interquartile range, ** p = 0.0011. ( B ). The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept measured by gamma counting. Results are presented as the median with the interquartile range. * p = 0.0328. ( C ). Representative images (vehicle n = 9, PU-WS13 n = 9) and quantification of CD206 staining in 4T1 tumors from mice treated or not with PU-WS13 from D11 up to D22. Results are presented as the median with the interquartile range. ** p = 0.0056.

Article Snippet: The tissues were then stained with a rabbit polyclonal antibody directed against CD206 (1/100; LS-B9805-200, Clinisciences, Nanterre, France), GRP94 antibody (1/100; LS B3418, Clinisciences, Nanterre, France), or against CD8 (1/200; NBP2-29475, Novusbio, Noyal Châtillon sur Seiche, France) overnight at 4 °C.

Techniques: Inhibition, In Vivo, Single Photon Emission Computed Tomography, Injection, Staining